Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lux

Showing results (31-40 of 233) with videos related to

Pageof 24
Sort By:
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|June 28, 2013
[S3 guideline--Diagnosis and treatment of colorectal carcinoma: relevance for radiologic imaging and interventions]T J Vogl, W Schmiegel, C Pox, et al.
Breast (Edinburgh, Scotland)|November 13, 2017
Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in GermanyM P Lux, N Nabieva, T Hildebrandt, et al.
Onkologie|October 8, 2010
Mitomycin C in patients with gynecological malignanciesLaura Kahmann, Ulrich Beyer, Grit Mehlhorn, et al.
Breast Care (Basel, Switzerland)|March 30, 2022
Awareness and Availability of Routine Germline <i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in GermanyMichael P Lux, Thomas Decker, Eva Diana Runkel, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 13, 2006
Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignanciesH Kreis, C R Loehberg, M P Lux, et al.
Breast Care (Basel, Switzerland)|February 24, 2017
The PI3K Pathway: Background and Treatment ApproachesMichael P Lux, Peter A Fasching, Michael G Schrauder, et al.
Onkologie|July 16, 2010
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 studyMichael P Lux, Claudia Reichelt, Diethelm Wallwiener, et al.
Journal of Cancer Research and Clinical Oncology|July 25, 2018
Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysisThomas Papathemelis, Dunja Hassas, Michael Gerken, et al.
Breast Cancer Research and Treatment|September 6, 2005
Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*K Heusinger, C Löhberg, M P Lux, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|April 7, 2007
Evaluation of mathematical models for breast cancer risk assessment in routine clinical usePeter A Fasching, Mayada R Bani, Carolin Nestle-Krämling, et al.
Pageof 24

Showing results (31-40 of 233) with videos related to

Sort By:
Pageof 24
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|June 28, 2013
[S3 guideline--Diagnosis and treatment of colorectal carcinoma: relevance for radiologic imaging and interventions]T J Vogl, W Schmiegel, C Pox, et al.
Breast (Edinburgh, Scotland)|November 13, 2017
Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in GermanyM P Lux, N Nabieva, T Hildebrandt, et al.
Onkologie|October 8, 2010
Mitomycin C in patients with gynecological malignanciesLaura Kahmann, Ulrich Beyer, Grit Mehlhorn, et al.
Breast Care (Basel, Switzerland)|March 30, 2022
Awareness and Availability of Routine Germline <i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in GermanyMichael P Lux, Thomas Decker, Eva Diana Runkel, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 13, 2006
Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignanciesH Kreis, C R Loehberg, M P Lux, et al.
Breast Care (Basel, Switzerland)|February 24, 2017
The PI3K Pathway: Background and Treatment ApproachesMichael P Lux, Peter A Fasching, Michael G Schrauder, et al.
Onkologie|July 16, 2010
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 studyMichael P Lux, Claudia Reichelt, Diethelm Wallwiener, et al.
Journal of Cancer Research and Clinical Oncology|July 25, 2018
Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysisThomas Papathemelis, Dunja Hassas, Michael Gerken, et al.
Breast Cancer Research and Treatment|September 6, 2005
Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*K Heusinger, C Löhberg, M P Lux, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|April 7, 2007
Evaluation of mathematical models for breast cancer risk assessment in routine clinical usePeter A Fasching, Mayada R Bani, Carolin Nestle-Krämling, et al.
Pageof 24